Zahra Yari1, Mina Movahedian2, Hossein Imani3, Seyed Moayed Alavian4, Mehdi Hedayati5, Azita Hekmatdoost6. 1. Student Research Committee, Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 2. Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology, Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 3. Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences (TUMS), Tehran, Iran. 4. Middle East Liver Diseases (MELD) Center, Tehran, Iran. 5. Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 6. Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology, Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Azita.Hekmatdoost@cw.bc.ca.
Abstract
PURPOSE: Hesperidin as an antioxidant flavonoid exerts anti-adipogenic, anti-inflammatory, anti-oxidant and anti-hypercholesterolemic effects. Besides, the increasing prevalence of metabolic syndrome (MetS) and its allied complications, on the one hand, and the willingness of individuals to use natural products for curing their diseases, on the other hand, led to the design of this study to evaluate the efficacy of hesperidin in normalizing the metabolic abnormalities in patients with MetS. METHODS: In this clinical trial with a parallel-group design, 49 patients with MetS received either 500-mg hesperidin or placebo, twice daily, for 12 weeks. Number of participants with treated MetS was considered as a primary end point. Anthropometric parameters, dietary intake, physical activity, lipid profile, glucose homeostasis parameter, tumor necrosis factor alpha (TNF-α), high-sensitivity C-reactive protein (hs-CRP) were assessed at the beginning and at the end of the study. This trial is registered at clinicaltrials.gov as NCT03734874. RESULTS: Compared with the placebo group, hesperidin decreased fasting glucose level (- 6.07 vs. - 13.32 mg/dL, P = 0.043), triglyceride (- 8.83 vs. - 49.09 mg/dL, P = 0.049), systolic blood pressure (- 0.58 vs. - 2.68 mmHg, P = 0.048) and TNF-α (- 1.29 vs. - 4.44 pg/mL, P = 0.009). Based on the within-group analysis, hesperidin led to significant decrease in serum levels of glucose, insulin, triglyceride, total cholesterol, low density lipoprotein cholesterol, TNF-α and hs-CRP, while in control group only glucose and insulin significantly decreased. CONCLUSIONS: The results indicate that hesperidin supplementation can improve metabolic abnormalities and inflammatory status in patients with MetS.
RCT Entities:
PURPOSE:Hesperidin as an antioxidant flavonoid exerts anti-adipogenic, anti-inflammatory, anti-oxidant and anti-hypercholesterolemic effects. Besides, the increasing prevalence of metabolic syndrome (MetS) and its allied complications, on the one hand, and the willingness of individuals to use natural products for curing their diseases, on the other hand, led to the design of this study to evaluate the efficacy of hesperidin in normalizing the metabolic abnormalities in patients with MetS. METHODS: In this clinical trial with a parallel-group design, 49 patients with MetS received either 500-mg hesperidin or placebo, twice daily, for 12 weeks. Number of participants with treated MetS was considered as a primary end point. Anthropometric parameters, dietary intake, physical activity, lipid profile, glucose homeostasis parameter, tumor necrosis factor alpha (TNF-α), high-sensitivity C-reactive protein (hs-CRP) were assessed at the beginning and at the end of the study. This trial is registered at clinicaltrials.gov as NCT03734874. RESULTS: Compared with the placebo group, hesperidin decreased fasting glucose level (- 6.07 vs. - 13.32 mg/dL, P = 0.043), triglyceride (- 8.83 vs. - 49.09 mg/dL, P = 0.049), systolic blood pressure (- 0.58 vs. - 2.68 mmHg, P = 0.048) and TNF-α (- 1.29 vs. - 4.44 pg/mL, P = 0.009). Based on the within-group analysis, hesperidin led to significant decrease in serum levels of glucose, insulin, triglyceride, total cholesterol, low density lipoprotein cholesterol, TNF-α and hs-CRP, while in control group only glucose and insulin significantly decreased. CONCLUSIONS: The results indicate that hesperidin supplementation can improve metabolic abnormalities and inflammatory status in patients with MetS.
Authors: Marc-Andre Cornier; Dana Dabelea; Teri L Hernandez; Rachel C Lindstrom; Amy J Steig; Nicole R Stob; Rachael E Van Pelt; Hong Wang; Robert H Eckel Journal: Endocr Rev Date: 2008-10-29 Impact factor: 19.871
Authors: R N Bergman; G W Van Citters; S D Mittelman; M K Dea; M Hamilton-Wessler; S P Kim; M Ellmerer Journal: J Investig Med Date: 2001-01 Impact factor: 2.895
Authors: Darcy B Carr; Kristina M Utzschneider; Rebecca L Hull; Keiichi Kodama; Barbara M Retzlaff; John D Brunzell; Jane B Shofer; Brian E Fish; Robert H Knopp; Steven E Kahn Journal: Diabetes Date: 2004-08 Impact factor: 9.461
Authors: Anthony J G Hanley; Andreas Festa; Ralph B D'Agostino; Lynne E Wagenknecht; Peter J Savage; Russell P Tracy; Mohammed F Saad; Steven M Haffner Journal: Diabetes Date: 2004-07 Impact factor: 9.461
Authors: Jorge Escobedo; Herman Schargrodsky; Beatriz Champagne; Honorio Silva; Carlos P Boissonnet; Raul Vinueza; Marta Torres; Rafael Hernandez; Elinor Wilson Journal: Cardiovasc Diabetol Date: 2009-09-26 Impact factor: 9.951
Authors: Anna Mas-Capdevila; Joan Teichenne; Cristina Domenech-Coca; Antoni Caimari; Josep M Del Bas; Xavier Escoté; Anna Crescenti Journal: Nutrients Date: 2020-05-20 Impact factor: 5.717
Authors: Henrique J C B Gouveia; Mercedes V Urquiza-Martínez; Raul Manhães-de-Castro; Bárbara J R Costa-de-Santana; José Pérez Villarreal; Rosalío Mercado-Camargo; Luz Torner; Jailane de Souza Aquino; Ana E Toscano; Omar Guzmán-Quevedo Journal: Int J Mol Sci Date: 2022-07-28 Impact factor: 6.208